{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T13:06:28Z","timestamp":1766667988689,"version":"3.41.2"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070985, 82170579"],"award-info":[{"award-number":["82070985, 82170579"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>With the increasing incidence and prevalence, Crohn\u2019s disease (CD) has become one of the most challenging diseases in both diagnosis and treatment of gastroenterology. Evaluation of the disease activity and mucosal healing guides clinical decisions regarding subsequent therapy for CD. In this study, we enrolled a total of 144 patients with CD and 239 healthy controls were enrolled. Clinical characteristics and laboratory parameters of enrolled subjects were retrieved from the electronic medical record database of our hospital. Serum cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA). Mucosa expression levels of inflammatory agents were measured by quantitative RT-PCR (qRT-PCR). We identified two neutrophil-based indexes, the neutrophil-to-albumin ratio (NAR) and neutrophil-to-bilirubin ratio (NBR), both of which had not yet been explored in CD or UC. NAR and NBR were significantly increased in patients with CD compared to those in healthy controls, and both indexes showed significantly positive correlations with CD activity and inflammatory load. In note, NAR and NBR showed better performance than blood neutrophil percentage, serum albumin, or bilirubin alone in these scenarios. More importantly, both NAR and NBR discriminated CD patients who completely or partially responded to infliximab (IFX) induction therapy from those with primary non-response. Our observations suggest that NAR and NBR may serve as promising biomarkers in the diagnosis and prediction of response to IFX therapy in CD.<\/jats:p>","DOI":"10.3389\/fimmu.2022.865968","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T07:10:14Z","timestamp":1646377814000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn\u2019s Disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhou","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.150","article-title":"The Global Burden of IBD: From 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1756284819856865","DOI":"10.1177\/1756284819856865","article-title":"Targeting Mucosal Healing in Crohn's Disease: What the Clinician Needs to Know","volume":"12","author":"Klenske","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of Scheduled and Episodic Treatment Strategies of Infliximab in Crohn's Disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302830","article-title":"Mucosal Healing in Inflammatory Bowel Diseases: A Systematic Review","volume":"61","author":"Neurath","year":"2012","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial Diagnosis, Monitoring of Known IBD, Detection of Complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of Inflammation is a Risk Factor for Colorectal Neoplasia in Ulcerative Colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cpph.19","article-title":"Biomarkers-A General Review","volume":"76","author":"Aronson","year":"2017","journal-title":"Curr Protoc Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318343","article-title":"A Blood-Based Prognostic Biomarker in IBD","volume":"68","author":"Biasci","year":"2019","journal-title":"Gut"},{"key":"B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's Disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy158","article-title":"Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review","volume":"13","author":"Gisbert","year":"2019","journal-title":"J Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190312113935","article-title":"Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials","volume":"25","author":"Lindholm","year":"2019","journal-title":"Curr Pharm Des"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.12.005","article-title":"Prevalence and Risk Factors for Colonic Perforation During Colonoscopy in Hospitalized Inflammatory Bowel Disease Patients","volume":"5","author":"Navaneethan","year":"2011","journal-title":"J Crohns Colitis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001140","article-title":"Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients With Inflammatory Bowel Disease","volume":"23","author":"Buisson","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","article-title":"Biomarkers of Inflammation in Inflammatory Bowel Disease","volume":"149","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2012.06.004","article-title":"Assessment of Neutrophil-Lymphocyte Ratio in Ulcerative Colitis: A Promising Marker in Predicting Disease Severity","volume":"36","author":"Torun","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1515\/jomb-2017-0050","article-title":"Platelet-To-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio Predict Mucosal Disease Severity in Ulcerative Colitis","volume":"37","author":"Akpinar","year":"2018","journal-title":"J Med Biochem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000427","article-title":"Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity","volume":"21","author":"Cherfane","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22709","article-title":"Low Serum Adiponectin is a Predictor of Progressing to Nonalcoholic Fatty Liver Disease","volume":"33","author":"Zhang","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5256460","DOI":"10.1155\/2019\/5256460","article-title":"The Relationship Between Serum Bilirubin and Inflammatory Bowel Disease","volume":"2019","author":"Zhao","year":"2019","journal-title":"Mediators Inflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307980","article-title":"miR-10a Inhibits Dendritic Cell Activation and Th1\/Th17 Cell Immune Responses in IBD","volume":"64","author":"Wu","year":"2015","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309389","article-title":"miR-301a Promotes Intestinal Mucosal Inflammation Through Induction of IL-17A and TNF-Alpha in IBD","volume":"65","author":"He","year":"2016","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1053\/j.gastro.2017.01.049","article-title":"MicroRNA 301a Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting Btg1","volume":"152","author":"He","year":"2017","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.01.055","article-title":"MicroRNA-425 Facilitates Pathogenic Th17 Cell Differentiation by Targeting Forkhead Box O1 (Foxo1) and Is Associated With Inflammatory Bowel Disease","volume":"496","author":"Yang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015664","article-title":"Low Serum Bilirubin, Albumin, and Uric Acid Levels in Patients With Crohn's Disease","volume":"98","author":"Su","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B26","article-title":"Measures of Diagnostic Accuracy: Basic Definitions","volume":"19","author":"Simundic","year":"2009","journal-title":"EJIFCC"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.069476","article-title":"Laboratory Markers in IBD: Useful, Magic, or Unnecessary Toys","volume":"55","author":"Vermeire","year":"2006","journal-title":"Gut"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00054725-200102000-00002","article-title":"Anti-Saccharomyces Cerevisiae Antibodies (ASCA), Phenotypes of IBD, and Intestinal Permeability: A Study in IBD Families","volume":"7","author":"Vermeire","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02417.x","article-title":"Anti-Saccharomyces Cerevisiae and Perinuclear Anti-Neutrophil Cytoplasmic Antibodies in Coeliac Disease Before and After Gluten-Free Diet","volume":"21","author":"Granito","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"B30","first-page":"296","article-title":"Anti-Saccharomyces Cerevisiae Antibodies (ASCA) in Coeliac Disease","volume":"55","author":"Granito","year":"2006","journal-title":"Gut"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.11.005","article-title":"Endoscopic Assessment and Treating to Target Increase the Likelihood of Mucosal Healing in Patients With Crohn's Disease","volume":"12","author":"Bouguen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2907-3","article-title":"Correlations of C-Reactive Protein Levels and Erythrocyte Sedimentation Rates With Endoscopic Activity Indices in Patients With Ulcerative Colitis","volume":"59","author":"Yoon","year":"2014","journal-title":"Dig Dis Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200209000-00003","article-title":"Role of Serology and Routine Laboratory Tests in Childhood Inflammatory Bowel Disease","volume":"8","author":"Khan","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices","volume":"103","author":"Langhorst","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"108235","DOI":"10.1016\/j.intimp.2021.108235","article-title":"Peripheral Blood Neutrophil-to-Lymphocyte Ratio in Inflammatory Bowel Disease and Disease Activity: A Meta-Analysis","volume":"101","author":"Fu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039860","article-title":"Association Between Neutrophil-to-Albumin Ratio and Mortality in Patients With Cardiogenic Shock: A Retrospective Cohort Study","volume":"10","author":"Peng","year":"2020","journal-title":"BMJ Open"},{"key":"B37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1590\/1806-9282.66.s2.77","article-title":"Neutrophil Count to Albumin Ratio as a New Predictor of Mortality in Patients With COVID-19 Infection","author":"Varim","year":"2020","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.12.084","article-title":"Neutrophil-To-Albumin Ratio as a Biomarker of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage","volume":"147","author":"Zhang","year":"2021","journal-title":"World Neurosurg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.3029864","article-title":"Bilirubin is an Antioxidant of Possible Physiological Importance","volume":"235","author":"Stocker","year":"1987","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.3.1887","article-title":"Bilirubin Possesses Powerful Immunomodulatory Activity and Suppresses Experimental Autoimmune Encephalomyelitis","volume":"181","author":"Liu","year":"2008","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00149.2014","article-title":"Bilirubin Prevents Acute DSS-Induced Colitis by Inhibiting Leukocyte Infiltration and Suppressing Upregulation of Inducible Nitric Oxide Synthase","volume":"309","author":"Zucker","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.654808","article-title":"Unconjugated Bilirubin Attenuates DSS-Induced Colitis Potentially via Enhancement of Bilirubin Reabsorption","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.crohns.2011.11.010","article-title":"A Functional Polymorphism in UGT1A1 Related to Hyperbilirubinemia Is Associated With a Decreased Risk for Crohn's Disease","volume":"6","author":"de Vries","year":"2012","journal-title":"J Crohns Colitis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv004","article-title":"Changes in Serum Trough Levels of Infliximab During Treatment Intensification But Not in Anti-Infliximab Antibody Detection Are Associated With Clinical Outcomes After Therapeutic Failure in Crohn's Disease","volume":"9","author":"Steenholdt","year":"2015","journal-title":"J Crohns Colitis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.07.055","article-title":"A Panel to Predict Long-Term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis","volume":"13","author":"Arias","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2016.1144781","article-title":"Prediction of Clinical and Endoscopic Responses to Anti-Tumor Necrosis Factor-Alpha Antibodies in Ulcerative Colitis","volume":"51","author":"Morita","year":"2016","journal-title":"Scand J Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.865968\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T07:10:19Z","timestamp":1646377819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.865968\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2022.865968"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.865968","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"article-number":"865968"}}